Efficacy and Safety of Deferiprone for Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Deferiprone shows potential in slowing motor symptom progression in Parkinson's disease, although its impact on brain iron levels remains inconclusive. Further large-scale, long-term studies are warranted to establish its clinical efficacy and safety.
Authors
- R Rohan
- Sridevi Ravi
- Dhruv Jayeshkumar Shah (ORCID: https://orcid.org/0009-0008-6696-7704)
- Deekshitha Alla (ORCID: https://orcid.org/0000-0003-4234-6141)
- Soujanya Tirupati
- Rakshna Ramsundar
- Aradhya Singh (ORCID: https://orcid.org/0009-0002-1936-6355)
- Sai Lokesh Moraboina (ORCID: https://orcid.org/0009-0002-4038-0928)
- Chandana Priya Digumurthy
- Jashika Mellamput
- Mrudula Alla
Institutions
- Andhra University (IN)
- Trinity Health (US)
- Massachusetts College of Pharmacy and Health Sciences (US)
- Sri Ramachandra Institute of Higher Education and Research (IN)
- Windsor University School of Medicine (KN)
- Narayana Dental College and Hospital (IN)
- Apollo Institute of Medical Sciences & Research (IN)
- JSS Medical College and Hospital (IN)
Publication Details
- Journal
- Clinical Neuropharmacology
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1097/wnf.0000000000000669
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00